Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Complete Resection of a Right-Sided Interventricular Septal Fibroma.

Picarelli D, Leone R, Surraco JL, Fernandez N, Antelo M, Grela C, Speyer J, Bianchi D, Rios M, Chiesa P.

World J Pediatr Congenit Heart Surg. 2018 Mar;9(2):242-243. doi: 10.1177/2150135117747830.

PMID:
29544414
2.

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S.

Breast Cancer Res Treat. 2018 Feb;168(1):57-67. doi: 10.1007/s10549-017-4570-4. Epub 2017 Nov 9.

PMID:
29124456
3.

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.

Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S.

Breast Cancer Res. 2017 Aug 2;19(1):89. doi: 10.1186/s13058-017-0879-5.

4.

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A.

Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5.

PMID:
27931751
5.

Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.

Adams S, Novik Y, Oratz R, Axelrod D, Speyer J, Tiersten A, Goldberg JD, Bhardwaj N, Unutmaz D, Demaria S, Formenti S.

J Clin Oncol. 2014 Oct 1;32(28):3204-5. doi: 10.1200/JCO.2014.56.1282. Epub 2014 Aug 4. No abstract available.

PMID:
25092780
6.

Prone breast intensity modulated radiation therapy: 5-year results.

Osa EO, DeWyngaert K, Roses D, Speyer J, Guth A, Axelrod D, Fenton Kerimian M, Goldberg JD, Formenti SC.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):899-906. doi: 10.1016/j.ijrobp.2014.03.036. Epub 2014 May 24.

7.

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.

Singh J, Novik Y, Stein S, Volm M, Meyers M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, Formenti S, Kyriakou V, Joseph B, Goldberg JD, Li X, Adams S, Tiersten A.

Breast Cancer Res. 2014 Mar 31;16(2):R32. doi: 10.1186/bcr3634.

8.

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S.

Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.

9.

Finding ovarian cancer.

Hartge P, Speyer JL.

J Natl Cancer Inst. 2012 Jan 18;104(2):82-3. doi: 10.1093/jnci/djr518. Epub 2012 Jan 13. No abstract available.

10.

Head-eye coordination during simulated orbiter landing.

Moore ST, MacDougall HG, Lesceu X, Speyer JJ, Wuyts F, Clark JB.

Aviat Space Environ Med. 2008 Sep;79(9):888-98.

PMID:
18785358
11.

Changes in unsettled infant sleep and maternal mood following admission to a parentcraft residential unit.

Matthey S, Speyer J.

Early Hum Dev. 2008 Sep;84(9):623-9. doi: 10.1016/j.earlhumdev.2008.04.003. Epub 2008 Jun 3.

PMID:
18511223
12.

Directed forgetting of recently recalled autobiographical memories.

Barnier AJ, Conway MA, Mayoh L, Speyer J, Avizmil O, Harris CB.

J Exp Psychol Gen. 2007 May;136(2):301-22.

PMID:
17500653
13.

Nonlinear signal mixing in a three-terminal molecular wire.

Liu C, Speyer J, Ovchinnikov IV, Neuhauser D.

J Chem Phys. 2007 Jan 14;126(2):024705.

PMID:
17228964
14.

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.

Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JD, Muggia F.

Gynecol Oncol. 2007 Mar;104(3):727-31. Epub 2006 Nov 28.

PMID:
17126894
15.

Robust control for convection suppression in a fluid layer: The effects of boundary properties, actuator lag, and major parameter uncertainties.

Or AC, Speyer JL.

Phys Rev E Stat Nonlin Soft Matter Phys. 2006 Apr;73(4 Pt 2):046307. Epub 2006 Apr 19.

PMID:
16711929
16.

Conductivity and gating of silicon ringchains.

Speyer JL, Ovchinnikov IV, Neuhauser D, Baugh D.

J Chem Phys. 2005 Sep 22;123(12):124704.

PMID:
16392508
17.

The efficacy of tailored print materials in promoting colorectal cancer screening: results from a randomized trial involving callers to the National Cancer Institute's Cancer Information Service.

Marcus AC, Mason M, Wolfe P, Rimer BK, Lipkus I, Strecher V, Warneke R, Morra ME, Allen AR, Davis SW, Gaier A, Graves C, Julesberg K, Nguyen L, Perocchia R, Speyer JB, Wagner D, Thomsen C, Bright MA.

J Health Commun. 2005;10 Suppl 1:83-104.

PMID:
16377602
18.

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.

Hochster HS, Plimack ER, Mandeli J, Wadler S, Runowicz C, Goldberg G, Speyer J, Wallach R, Muggia F; New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology.

Gynecol Oncol. 2006 Feb;100(2):324-9. Epub 2005 Oct 25.

PMID:
16253316
19.

Gain-scheduled controller for the suppression of convection at high Rayleigh number.

Or AC, Speyer JL.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Apr;71(4 Pt 2):046302. Epub 2005 Apr 4.

PMID:
15903781
20.

Control of satellite clusters in elliptic orbit with limited communication.

Chichka DF, Belanger G, Speyer JL.

Ann N Y Acad Sci. 2004 May;1017:177-89.

PMID:
15220147
21.

A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.

Pavlick AC, Chodkiewicz C, Liebes L, Hamilton A, Wasserheit C, Hochster H, Speyer J, Phillips Z, Downey A, Sorich J, Muggia F.

Anticancer Drugs. 2004 Feb;15(2):119-25.

PMID:
15075667
22.

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM.

J Clin Oncol. 2004 Jan 1;22(1):120-6.

PMID:
14701774
23.

Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.

Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F.

J Clin Oncol. 2003 Jul 15;21(14):2703-7.

PMID:
12860947
24.

Electronic pilot-activity monitor: a countermeasure against fatigue on long-haul flights.

Cabon P, Bourgeois-Bougrine S, Mollard R, Coblentz A, Speyer JJ.

Aviat Space Environ Med. 2003 Jun;74(6 Pt 1):679-82.

PMID:
12793543
25.

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.

Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L.

Oncologist. 2002;7(5):410-7.

26.

Cardiac dysfunction in the trastuzumab clinical experience.

Speyer J.

J Clin Oncol. 2002 Mar 1;20(5):1156-7. No abstract available.

PMID:
11870153
27.

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer JL, Newcomb EW.

Hum Pathol. 2001 Aug;32(8):808-13.

PMID:
11521224
28.

Coping with cancer: the impact of the Cancer Information Service on patients and significant others. Part 6.

Darrow SL, Speyer J, Marcus AC, Ter Maat J, Krome D.

J Health Commun. 1998;3 Suppl:86-96.

PMID:
10977272
29.

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.

Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B, Speyer J.

J Clin Oncol. 1999 Aug;17(8):2553-61.

PMID:
10561322
30.

Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.

Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ.

J Clin Oncol. 1999 Mar;17(3):880-6.

PMID:
10071279
32.

Doxorubicin-induced cardiomyopathy.

Muggia FM, Speyer JL.

N Engl J Med. 1999 Feb 25;340(8):654-5. No abstract available.

PMID:
10049088
33.

PSC833: initial clinical results in refractory ovarian cancer patients.

Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L.

Curr Opin Oncol. 1998 Aug;10 Suppl 1:S21. No abstract available.

PMID:
9988540
34.

Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors.

Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL.

Am J Pathol. 1999 Jan;154(1):119-25.

35.

Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.

Rosenthal MA, Dennis D, Liebes L, Furmanski P, Caron D, Garrison L, Wiprovnick J, Peace D, Oratz R, Speyer J, Chachoua A.

J Immunother. 1998 Sep;21(5):371-8.

PMID:
9789199
36.

Strategies for reduction of anthracycline cardiac toxicity.

Speyer J, Wasserheit C.

Semin Oncol. 1998 Oct;25(5):525-37. Review.

PMID:
9783592
37.
38.

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.

Clin Cancer Res. 1997 Aug;3(8):1245-52.

39.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA.

J Clin Oncol. 1997 Apr;15(4):1318-32.

PMID:
9193323
40.

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J.

J Clin Oncol. 1996 Jul;14(7):1993-9. Erratum in: J Clin Oncol 1996 Dec;14(12):3175.

PMID:
8683229
41.

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.

Runowicz CD, Mandeli J, Speyer JL, Wadler S, Hochster H, Garrison L, Holland JF.

Am J Obstet Gynecol. 1996 Apr;174(4):1151-9; discussion 1159-60.

PMID:
8623842
42.

Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.

Morgan RJ Jr, Speyer J, Doroshow JH, Margolin K, Raschko J, Sorich J, Akman S, Leong L, Somlo G, Vasilev S, et al.

Gynecol Oncol. 1995 Jul;58(1):79-85.

PMID:
7789895
43.

Cardiotoxicity and cardioprotection during chemotherapy.

Hochster H, Wasserheit C, Speyer J.

Curr Opin Oncol. 1995 Jul;7(4):304-9. Review.

PMID:
7578376
44.

A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.

Speyer JL, Mandeli J, Hochster H, Runowicz C, Wadler S, Wallach R, Cohen C, Oette D, Sorich J, Demakos E, et al.

Gynecol Oncol. 1995 Mar;56(3):387-94.

PMID:
7705673
45.

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al.

J Clin Oncol. 1994 Mar;12(3):553-9.

PMID:
8120553
46.

Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.

Wadler S, Beitler JJ, Rubin JS, Haynes H, McGill F, Rozenblit A, Goldberg G, Cohen C, Speyer J, Runowicz C.

J Clin Oncol. 1993 Aug;11(8):1511-6.

PMID:
8393096
47.
48.

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL.

J Natl Cancer Inst. 1992 Nov 18;84(22):1725-30.

PMID:
1433357
49.

Intraperitoneal carboplatin: rationale and experience.

Speyer JL, Sorich J.

Semin Oncol. 1992 Feb;19(1 Suppl 2):107-13. Review.

PMID:
1411621
50.

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Walsh C, Blum RH, Oratz R, Goldenberg A, Downey A, Speyer JL.

J Cancer Res Clin Oncol. 1992;118(1):61-6.

PMID:
1729261

Supplemental Content

Loading ...
Support Center